Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts

NCT00189293 is registered in ClinicalTrials.gov with MEDA Pharma GmbH & Co. KG as lead sponsor.

NCT NCT00189293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts
Lead sponsor
MEDA Pharma GmbH & Co. KG
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2005
Completion date
December 31, 2007
Enrollment
128 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

genital warts